Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The prevalence of obesity and diabetes is an increasing global problem, especially in developed countries, and is referred to as the twin epidemics. As such, advanced treatment approaches are needed. Tirzepatide, known as a ‘twincretin’, is a ‘first-in-class’ and the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, that can significantly reduce glycemic levels and improve insulin sensitivity, as well as reducing body weight by more than 20% and improving lipid metabolism. This novel anti-diabetic drug is a synthetic peptide analog of the human GIP hormone with a C20 fatty-diacid portion attached which, via acylation technology, can bind to albumin in order to provide a dose of the drug, by means of subcutaneous injection, once a week, which is appropriate to its a half-life of about five days. Tirzepatide, developed by Eli Lilly, was approved, under the brand name Mounjaro, by the United States Food and Drug Administration in May 2022. This started the ‘twincretin’ era of enormously important and appealing dual therapeutic options for diabetes and obesity, as well as advanced management of closely related cardiometabolic settings, which constitute the leading cause of morbidity, disability, and mortality worldwide. Herein, we present the key characteristics of tirzepatide in terms of synthesis, structure, and activity, bearing in mind its advantages and shortcomings. Furthermore, we briefly trace the evolution of this kind of medical agent and discuss the development of clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, tirzepatide lowers systolic blood pressure in adults who are obese, which can reduce the risk of hypertension and cardiovascular issues (86–88).”
From A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tirzepatide is a novel pharmacological class that acts as GLP-1/GIP receptor agonist.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · PubMed · Cited by 13,173
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855 · cited 1×
“It should be highlighted that obesity is related to an increased risk of other serious conditions and diseases such as diabetes, hypertension, cardiovascular disease, cancer, asthma, hypercholesterolemia, and so on [7].”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“Subcutaneous administration once a week is adequate, as it possesses a half-life of about 5 days [29].”
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 2×
“The adverse events most commonly reported were nausea, vomiting, and diarrhea, which were mild to moderate and occurred mostly during the dose-escalation period [40,54].”
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 2×
“…‐ 4 (DPP ‐ 4) inhibitors act by obstructing the quick DPP ‐ 4 ‐ me ‐ diated degradation of endogenous GLP ‐ 1 and GIP, enhancing their effectiveness. action in T2D patients, GIP infusion does not bring out a significant insulin response, even at pharmacological concentrations [24].”
Morbidity and mortality associated with obesity
Abdelaal, M., le Roux, C. W., & Docherty, N. G. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.03.107 · Cited by 1,052
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 1×
“More specifically, the structure is based on the native GIP sequence and includes C20 fatty diacid moiety (eicosanedioic acid) linked via hydrophilic linkers ( γ -Glu-2xAdo, gamma glutamate and bis-aminodiethoxyacetyl) connected to lysine residue at C20 position [31].”
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 4×
“The most common side effects associated with tirzepatide are related to gastrointestinal tract like nausea, vomiting and diarrhea [20,21].”
Influential
Research works printed but not linked: 3
- World Health Organization Obesity: Preventing and Managing the Global Epidemic Technical Report WHO Geneva, Switzerland 2000 11234459
- Costello R.A. Shivkumar N.S. Sulfonylureas Updated 23 February 2022 StatPearls Publishing Treasure Island, FL, USA 2022 30020597
- Tupas G.D. Otero M.C.B. Ebhohimen I.E. Egbuna C. Aslam M. Chapter 8—Antidiabetic Lead Compounds and Targets for Drug Development Phytochemicals as Lead Compounds for New Drug Discovery Egbuna C. Kumar S. Ifemeje J.C. Ezzat S.M. Kaliyaperumal S. Elsevier Amsterdam, The Netherlands 2020 127 141
Cited by
Hickey, J. L., Sindhikara, D., Zultanski, S. L., & Schultz, D. M. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00037 · Cited by 178
Lombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 146
Glucagon‐like peptide agonists: A prospective review
Mariam, Z., & Niazi, S. K. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.462 · Cited by 130
Peptide-Drug Conjugates: A New Hope for Cancer Management
Chavda, V. P., Solanki, H. K., Davidson, M., Apostolopoulos, V., & Bojarska, J. (2022) · Molecules · doi:10.3390/molecules27217232 · Cited by 106
Self-citationGallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
Varney, M. J., & Benovic, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001015 · Cited by 89
Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1214334 · Cited by 66
Tegegne, B. A., Adugna, A., Yenet, A., Yihunie Belay, W., Yibeltal, Y., Dagne, A., Hibstu Teffera, Z., Amare, G. A., Abebaw, D., Tewabe, H., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1440456 · Cited by 61
de Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01337-x · Cited by 59
“Trials that had a placebo and additional control groups were included, but only the placebo control group was analyzed.”
BackgroundLegume-Derived Bioactive Peptides in Type 2 Diabetes: Opportunities and Challenges
Hu, K., Huang, H., Li, H., Wei, Y., & Yao, C. (2023) · Nutrients · doi:10.3390/nu15051096 · Cited by 71
Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials
Kanbay, M., Copur, S., Siriopol, D., Yildiz, A. B., Gaipov, A., van Raalte, D. H., & Tuttle, K. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15272 · Cited by 56
Llewellyn, D. C., Logan Ellis, H., Aylwin, S. J. B., Oštarijaš, E., Green, S., Sheridan, W., Chew, N. W. S., le Roux, C. W., Miras, A. D., Patel, A. G., et al. (2023) · Obesity · doi:10.1002/oby.23600 · Cited by 54
Zaffina, I., Pelle, M. C., Armentaro, G., Giofrè, F., Cassano, V., Sciacqua, A., & Arturi, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1095753 · Cited by 56
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Corrao, S., Pollicino, C., Maggio, D., Torres, A., & Argano, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1402583 · Cited by 62
Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery
Domingues, I., Leclercq, I. A., & Beloqui, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.040 · Cited by 45
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
Almeida, G. D. O., Nienkotter, T. F., Balieiro, C. C. A., Pasqualotto, E., Cintra, J. B., Carvalho, H. C. P., Silva, A. L. S., Kabariti, J. C., Minucci, B. S., Bertoli, E. D., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00647-3 · Cited by 54
Hropot, T., Herman, R., Janez, A., Lezaic, L., & Jensterle, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108592 · Cited by 39
Beyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 44
Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management
Wojtara, M., Mazumder, A., Syeda, Y., & Mozgała, N. (2023) · Advances in Medicine · doi:10.1155/2023/9946924 · Cited by 36
The promise of tirzepatide: A narrative review of metabolic benefits
Sokary, S., & Bawadi, H. A. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.03.008 · Cited by 44
Clickable tryptophan modification for late-stage diversification of native peptides
Xiao, Y., Zhou, H., Shi, P., Zhao, X., Liu, H., & Li, X. (2024) · Science Advances · doi:10.1126/sciadv.adp9958 · Cited by 39
Diabetic Cardiomyopathy—From Basics through Diagnosis to Treatment
Radzioch, E., Dąbek, B., Balcerczyk-Lis, M., Frąk, W., Fularski, P., Młynarska, E., Rysz, J., & Franczyk, B. (2024) · Biomedicines · doi:10.3390/biomedicines12040765 · Cited by 44
Lempesis, I. G., Liu, J., & Dalamaga, Μ. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100220 · Cited by 38
The Impact of Obesity on Inflammatory Bowel Disease
Kaazan, P., Seow, W., Yong, S., Heilbronn, L. K., & Segal, J. P. (2023) · Biomedicines · doi:10.3390/biomedicines11123256 · Cited by 36
360-Degree Perspectives on Obesity
Cuciureanu, M. D., Caratașu, C.-C., Gabrielian, L., Frăsinariu, O. E., Checheriță, L. E., Trandafir, L. M., Stanciu, G. D., Szilagyi, A., Pogonea, I., Bordeianu, G., et al. (2023) · Medicina · doi:10.3390/medicina59061119 · Cited by 37
Tirzepatida: Un Avance Revolucionario en el Tratamiento de la Diabetes Mellitus Tipo 2 y la Obesidad
Chávez, M. (2023) · Revista Veritas de Difusão Cientifica. · doi:10.61616/rvdc.v4i1.39 · Cited by 35
The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
Anala, A. D., Saifudeen, I. S. H., Ibrahim, M., Nanda, M., Naaz, N., & Atkin, S. L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144575 · Cited by 39
Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
Dutta, P., Kumar, Y., Babu, A. T., Ravindran, S. G., Salam, A., Rai, B., Baskar, A., Dhawan, A., & Jomy, M. (2023) · Cureus · doi:10.7759/cureus.38379 · Cited by 46
Unlocking Longevity with GLP-1: A Key to Turn Back the Clock?
Chavda, V. P., Balar, P. C., Vaghela, D. A., & Dodiya, P. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108028 · Cited by 24
Self-citationPharmacotherapy before and after bariatric surgery
Alabduljabbar, K. A., & le Roux, C. W. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155692 · Cited by 30
Danpanichkul, P., Manosroi, W., Nilsirisuk, T., & Tosukhowong, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1251798 · Cited by 31
Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Maio, G. D., Monda, M., & Marra, M. L. (2025) · Healthcare · doi:10.3390/healthcare13121437 · Cited by 37
Wright, E. E., Roberts, G. J., Chuang, J. S., Nabutovsky, Y., Virdi, N., & Miller, E. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0015 · Cited by 22
Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management
Alhomoud, I. S., Talasaz, A. H., Chandrasekaran, P., Brown, R., Mehta, A., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4607 · Cited by 28
Role of metformin in the management of type 2 diabetes: recent advances
Gonzalez-Lopez, C., & Wojeck, B. S. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16511 · Cited by 28
An Insight into the Combat Strategies for the Treatment of Type 2 Diabetes Mellitus
Chawla, G., Pradhan, T., & Gupta, O. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230517113936 · Cited by 20
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Kumar, A., Mazumder, R., Rani, A., Pandey, P., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998261903230921102620 · Cited by 24
A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease
Alshehri, G. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Fawzy, M. N., Waheed, H. J., Papadakis, M., Alexiou, A. T., & Batiha, G. E. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177979 · Cited by 20
Rohani, P., Malekpour Alamdari, N., Bagheri, S. E., Hekmatdoost, A., & Sohouli, M. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1230206 · Cited by 18
Sallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Batiha, G. E., Al-Kuraishy, H. M., Al-Gareeb, A. I., Ashour, N. A., & Negm, W. A. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01239-4 · Cited by 19
Infante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 20
Catalfamo, L. M., Ponte, F. S. D., & Rinaldis, D. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155269 · Cited by 25
Onikanni, S. A., Lawal, B., Munyembaraga, V., Bakare, O. S., Taher, M., Khotib, J., Darnis, D. S., Oyinloye, B. E., Noriega, L., Famuti, A., et al. (2023) · Molecules · doi:10.3390/molecules28155752 · Cited by 19
Gallagher, D. M., O'Harte, F. P. M., & Irwin, N. (2023) · Peptides · doi:10.1016/j.peptides.2023.171096 · Cited by 19
Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Bhopale, K. K., & Srinivasan, M. P. (2023) · Livers · doi:10.3390/livers3040040 · Cited by 19
Willson, C. M., Patel, L., Middleton, P., & Desai, M. M. (2024) · Cureus · doi:10.7759/cureus.58042 · Cited by 26
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02465-x · Cited by 18
McGill, J. B., Hirsch, I. B., Parkin, C. G., Aleppo, G., Levy, C. J., & Gavin, J. R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01569-8 · Cited by 28
Gadgaard, S., Windeløv, J. A., Schiellerup, S. P., Holst, J. J., Hartmann, B., & ROSENKILDE, M. M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114383 · Cited by 17
Abubakar, M., Nama, L., Ansari, M. M., Ansari, M. M., Bhardwaj, S., Daksh, R., Syamala, K. L. V., Jamadade, M. S., Chhabra, V., Kumar, D., et al. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266293416240515075450 · Cited by 18
Tirzepatide: a novel therapeutic approach for Alzheimer’s disease
Alshehri, G. H., Al-Kuraishy, H. M., Waheed, H. J., Al-Gareeb, A. I., Faheem, S. A., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01649-z · Cited by 21
Reitz, J., Rosoff, D. B., Perlstein, T., Wagner, A., Jung, J., Wagner, J., Reiner, B. C., & Lohoff, F. W. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03199-3 · Cited by 18
Wong, M.-T., Lin, P.-H., Lin, W., Peng, C., Wright, J. D., Lee, H.-J., Chu, H., Lim, C., & Chang, T. W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02153 · Cited by 13
Liarakos, A. L., & Koliaki, C. C. (2023) · Biomedicines · doi:10.3390/biomedicines11071875 · Cited by 16
Self-assembled peptide hydrogels for the treatment of diabetes and associated complications
Chavda, V. P., Teli, D., Balar, P. C., Davidson, M., Bojarska, J., Vaghela, D. A., & Apostolopoulos, V. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.113761 · Cited by 12
Self-citationAli, A., Flatt, P. R., & Irwin, N. (2024) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514241238059 · Cited by 13
Abutaima, R., Barakat, M. M., Sawan, H. M., Omari, S. M. A., & Mhaidat, N. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314407 · Cited by 20
Synergistic Beneficial Effects of Resveratrol and Diet on High-Fat Diet-Induced Obesity
Alrob, O. A., Al-Horani, R., Altaany, Z., & Nusair, M. B. (2022) · Medicina · doi:10.3390/medicina58091301 · Cited by 15
Feng, P., Liu, Z., Lv, D., Hao, W., Li, D., Xue, G., Bai, B., & Hölscher, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177972 · Cited by 11
Tirzepatide for Weight Loss: Can Medical Therapy “Outweigh” Bariatric Surgery?
Novograd, J., Mullally, J. A., & Frishman, W. H. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000515 · Cited by 12
Tirzepatide-related acute liver injury
Abdullah, I., El-Ghousain, H., & Alenezi, M. (2024) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2024_004813 · Cited by 11
Alqifari, S. F., Komi, O. A., Esmail, A., Alkhawami, K., Yousri, S., Muqresh, M. A., Alharbi, N., Khojah, A. A. A., Aljabri, A. M., Allahham, A., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i3.331 · Cited by 11
Nag, S., Mitra, O., Maturi, B., Kaur, S. P., Saini, A., Nama, M., Roy, S., Samanta, S., Chacko, L., Dutta, R., et al. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100927 · Cited by 18
Al-Sabah, S. K., Al‐Khairi, I., Jamal, M. H., Qaddoumi, M. G., Al-Ajmi, F. A., Kumar, J., ABUKHALAF, N. A., Cherian, P., Madhu, D., Arefanian, H., et al. (2024) · Medical Principles and Practice · doi:10.1159/000540534 · Cited by 14
Miller, E., Chuang, J. S., Roberts, G. J., Nabutovsky, Y., Virdi, N., & Wright, E. E. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01619-1 · Cited by 9
Ceriello, A., Rodbard, H. W., Battelino, T., Brosius, F. C., Cosentino, F., Green, J., Ji, L., Kellerer, M., Koob, S., Kosiborod, M., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01993-3 · Cited by 12
Tirzepatide a novel anti diabetic molecule unfold dual action
Sweta, Gupta, S., Bansal, S., Devi, S., Sharma, S., Laxmi, L., & Deepa (2024) · Discover Public Health · doi:10.1186/s12982-024-00200-2 · Cited by 14
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
Ghaleb, J., Khouzami, K. K., Nassif, N., Attieh, P., Ajlani, M. F. A., Sleiman, J. B., Khalouf, A., Harb, F., Azar, S. T., Kanaan, A., et al. (2025) · International Journal of Endocrinology · doi:10.1155/ije/2876156 · Cited by 11
Vekić, J., Zeljković, A., Maggio, V., Rizzo, M., & Medenica, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01828-2 · Cited by 10
Ahmed, M., Badi, S., Elidrisi, A., Husain, N. E., Zainudin, S. B., Mahmood, A., Abubaker, N. E., Alghamdi, A., & Ahmed, M. H. (2022) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-022-01145-6 · Cited by 12
Gomes, A. F. T., de Medeiros, W. F., de Oliveira, G. S., Medeiros, I., da Silva-Maia, J. K., Bezerra, I. W. L., Piuvezam, G., & Morais, A. H. D. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279039 · Cited by 9
Hirsch, I. B., Parkin, C. G., Cavaiola, T. S., & Bergenstal, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15883 · Cited by 8
Cazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8
“GIP, an incretin hormone secreted by K-cells of the upper small intestine, complements GLP-1 in stimulating glucose-dependent insulin release, while also contributing to adipose tissue regulation [42–45].”
Unveiling resveratrol's potential: Navigating the landscape of autoimmune diseases
Jetha, K. L., Vyas, A., Tripathi, A., Gandhi, J., & Chavda, V. P. (2024) · Clinical Traditional Medicine and Pharmacology · doi:10.1016/j.ctmp.2024.200145 · Cited by 9
Self-citationTokarewicz, J., Jankowiak, B., Klimaszewska, K., Święczkowski, M., Matlak, K., & Dobrzycki, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030729 · Cited by 16
Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy
Ma, J., Mao, L., Yang, L., Xie, Q., Fan, R., Lu, X., Huang, X., Tong, N., & Duan, Z. (2025) · MedComm · doi:10.1002/mco2.70359 · Cited by 20
Luca, C. D., Nosengo, C., Spedicato, M., Magagnato, L., Fogli, G., Carraro, M., Cabri, W., Macis, M., Cavazzini, A., Felletti, S., et al. (2025) · Green Chemistry · doi:10.1039/d5gc01158b · Cited by 9
Supramolecular synthon hierarchy in cyclopropyl-containing peptide-derived compounds
Bojarska, J., Breza, M., Remko, M., Borowiecki, P., Fruziñski, A., Madura, I. D., Kaczmarek, K., Lesnikowski, Z. J., Kraj, A., Zielenkiewicz, P., et al. (2022) · CrystEngComm · doi:10.1039/d2ce01231f · Cited by 8
Self-citationMartins, A. C., de la Torre, B. G., & Alberício, F. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00039 · Cited by 11
Recent and Upcoming Therapies for Management of Type 2 Diabetes: A Review
Gokalani, R. A., Saiyed, M., Dey, A. K., & Sheikh, F. (2024) · Preventive Medicine Research & Reviews · doi:10.4103/pmrr.pmrr_12_24 · Cited by 8
Oral delivery of protein and peptide therapeutics
Chavda, V. P., & Balar, P. C. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.11.003 · Cited by 8
Self-citationPawlas, J., & Lindgren, A. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c00423 · Cited by 8
Real-World Safety Concerns of Tirzepatide: A Retrospective Analysis of FAERS Data (2022–2025)
Almansour, H. A., Thaibah, H. A., Alfarhan, M., Al-Qahtani, S. A., Khardali, A., & Alshammari, T. M. (2025) · Healthcare · doi:10.3390/healthcare13182259 · Cited by 18
Clinical Trials in Diabetes: Examining the Value of Use of Continuous Dual Glucose-Ketone Monitoring
Aktürk, H. K., Perkins, B. A., & Dunn, T. C. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251390818 · Cited by 8
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
Tirzepatide Affect Sexual Function in Women: Case Report
Mohammed, G. F., Al‐Dhubaibi, M. S., Bahaj, S. S., & Mohammed, R. M. (2025) · Clinical Medicine Insights Case Reports · doi:10.1177/11795476251347753 · Cited by 6
Fiorucci, S., & Urbani, G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2546812 · Cited by 10
Lipid regulation of the glucagon receptor family
Oqua, A. I., Manchanda, Y., McGlone, E. R., Jones, B. J., Rouse, S. L., & Tomás, A. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0335 · Cited by 8
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
Liu, B., Shao, T., Xiao, D., Yang, S., Lin, W., Sun, L., Zhang, W., Luo, M., Zhao, J., Yang, L., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119330 · Cited by 7
Gojani, E. G., Wang, B., Li, D., Kovalchuk, O., & Kovalchuk, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26010421 · Cited by 9
Tirzepatide: A First-in-class Twincretin for the Management of Type 2 Diabetes
Jaswal, S., Bisht, P., Patel, R., Parveen, D., Gupta, G. D., & Verma, S. K. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230130153219 · Cited by 5
Orlandin, A., Guryanov, I., Giraldo, C., Biondi, B., Santoro, A., Macis, M., Cabri, W., D’Ursi, A. M., Glisenti, A., Formaggio, F., et al. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.4c00515 · Cited by 5
Beyond glycemic control: the neuroprotective potential of tirzepatide
Hristov, M., Cheema, G., Ali, H., & Andreeva-Gateva, P. A. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e155150 · Cited by 7
Pawlas, J., Billing, J. F., Tebikachew, B. E., Wahlström, L., & Haugaard‐Kedström, L. M. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00341 · Cited by 6
Metadata
- Authors
- Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V.
- Affiliations
- Department of Pharmaceutics and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad 380009, India
- Department of Pharmaceutics Analysis and Quality Assurance, LM College of Pharmacy, Ahmedabad 380009, India
- Department of Pharmaceutical Chemistry, LM College of Pharmacy, Ahmedabad 380009, India
- Lodz University of Technology (PL)
- Australian Institute for Musculoskeletal Science (AU)
- Corresponding author
- Chavda, Vivek P.
- Bojarska, Joanna
- Apostolopoulos, Vasso
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-07-05
- Volume
- 27
- Issue
- 13
- Pages
- 4315
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC9268041
- OpenAlex
- W4283834854
- Cited by
- 208
- References
- 57
- Citations by year
- 2026: 40 · 2025: 59 · 2024: 49 · 2023: 49 · 2022: 11
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-07-05)
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Victoria University Research Repository (Victoria University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- tirzepatide, GIP/GLP-1 receptor agonist, type 2 diabetes, obesity, glycemic control, insulin sensitivity, weight loss, lipid metabolism, albumin binding, acylation, Mounjaro, cardiometabolic disease, drug development
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.